The Latest Cardiac and Vascular News
Financing led by Andera Partners including Cormorant Asset Management, Taglich Brothers Inc., Squarepoint Capital, and Richmond Brothers to Support Premarket Approval of Revivent TC® System for Patients with Ischemic Heart Failure MANSFIELD, Mass., April 13, 2023 /PRNewswire/ — BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left […]
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy MANSFIELD, Mass., March 15, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, […]
Brings Extensive Clinical Trial and Patient Care Experience to Senior Management Team SAN RAMON, Calif., Feb. 8, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart […]
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ — BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart […]
Revolutionary Heart Failure Therapy Company Also Adds New Executive and Well-Known Board Member to Enhance Expertise SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), today […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen […]
Proven Leader Will Take Revolutionary Heart Failure Therapy Company to Next Level SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO. In his role, Mr. […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE™ Therapy using the Revivent TC™ […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible for driving enrollment in the ongoing ALIVE Trial […]
